Cholesterol-Lowering drug may boost lung cancer immunotherapy
NCT ID NCT07061535
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding tafolecimab (a cholesterol-lowering drug) to standard chemotherapy and the immunotherapy sintilimab helps people with extensive-stage small cell lung cancer live longer without their cancer growing. About 40 adults who have not had prior treatment for this advanced lung cancer will receive all three drugs together. The study measures how long the cancer stays under control and how well patients respond.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sintilimab, tafolecimab, etoposide, carboplatin or cisplatin
What this could lead to
If successful, this combination could offer a new first-line treatment option that improves how long people with extensive-stage small cell lung cancer live without their disease worsening.
What could go wrong
This is an early-phase, single-arm trial with only 40 participants, so results may not apply broadly. Adding tafolecimab to standard therapy may increase side effects without clear benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences
RECRUITINGHangzhou, Zhejiang, China
Contact Email: •••••@•••••
-
First Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITINGHangzhou, Zhejiang, China
Contact Email: •••••@•••••
-
Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
NOT_YET_RECRUITINGChangsha, Hunan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Second Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITINGHangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science
RECRUITINGJinan, Shandong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••